2277. Cilostazol

Nomenclature

CAS number: 73963-72-1
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril; 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4-tetrahydro-2-oxoquinoline; OPC-13013; Pletal (Otsuka).
C20H27N5O2; mol wt 369.46.
C 65.02%, H 7.37%, N 18.96%, O 8.66%.

Description and references

Phosphodiesterase (PDE III) inhibitor; induces vasodilation and inhibits platelet aggregation. Prepn: BE 878548; T. Nishi, K. Nakagawa, US 4277479 (1979, 1981 both to Otsuka); T. Nishi et al., Chem. Pharm. Bull. 31, 1151 (1983). Physical properties: T. Shimizu et al., Arzneim.-Forsch. 35, 1117 (1985). HPLC determn in plasma: H. Akiyama et al., J. Chromatogr. 338, 456 (1985). Acute toxicity study: G. Nomura et al., Iyakuhin Kenkyu 16, 1200 (1985), C.A. 104, 102207f (1986). Clinical pharmacokinetics: A. Suri et al., J. Clin. Pharmacol. 38, 144 (1998). Clinical evaluation to prevent stent thrombosis: S.-W. Park et al., Am. J. Cardiol. 84, 511 (1999); to prevent restenosis after angioplasty: E. Tsuchikane et al., Circulation 100, 21 (1999). Review of pharmacology and clinical efficacy in intermittent claudication: E. M. Sorkin, A. Markham, Drugs Aging 14, 63-71 (1999).

Chemical structure

Properties

Colorless needle-like crystals from methanol, mp 159.4-160.3°. uv max (methanol): 257 nm (ε 15200). Freely sol in acetic acid, chloroform, n-methyl-2-pyrrolidone, DMSO. Practically insol in ether, water, 0.1N HCl, 0.1N NaOH. LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura).

Therapeutic Category

Antithrombotic; in treatment of intermittent claudication.

Keywords

Antithrombotic; Phosphodiesterase Inhibitor